Firefly Bio, Inc. is a biotechnology company headquartered in South San Francisco, California. It develops degrader antibody conjugates (DACs) via its proprietary Firelink platform, which targets selective protein degradation in tumor cells for KRAS-driven and other solid cancers.
On June 8, 2026, Johnson & Johnson announced a definitive agreement to acquire the company for $1 billion in cash, subject to regulatory approvals, with closing expected later in 2026.
Official website: fireflybiologics.com
To provide comprehensive coverage, we aggregate data and news under the name Firefly Bio, encompassing the following company names, divisions, and related entities:
Firefly Bio Inc. and Firefly Biologics.
This list encompasses current and former names, alternate names, and key divisions associated with Firefly Bio, ensuring you can easily find all relevant information under a single, unified profile.
